|
Sign In to gain access to subscriptions and/or personal tools.
|
New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial
Cristina Sierra
Hypertension Units, Hospital Clinic of Barcelona & Hospital Doce de Octubre, Madrid, Spain
Luis M Ruilope
Hypertension Units, Hospital Clinic of Barcelona & Hospital Doce de Octubre, Madrid, Spain, Luis_m_Ruilope{at}teleline.es
The development of new-onset diabetes is frequent during the follow-up of treated hypertensive patients. The prevalence of such an event seems to differ depending on the type of antihypertensive therapy used to control blood pressure. Diuretics and -blockers and their association are particularly harmful in this regard. On the contrary, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, alone or in association with diuretics, are associated with a lower prevalence of this metabolic complication. These statements are confirmed by data from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study. Longterm studies are required to determine the relevance of development of new-onset diabetes in treated hypertensive patients.
Key Words: new-onset diabetes • arterial hypertension • antihypertensive therapy • diuretics • angiotensin receptor blockers
References
- ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-97.[Abstract/Free Full Text]
- Kaplan NM The meaning of ALLHAT. J Hypertens 2003; 21:233-4.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Murphy MB, Lewis PJ, Kohner E., Schumer B., Dollery CT Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet 1982;2:1293-5.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lithell H. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens 1996;9:150S-154S.[CrossRef][Medline]
[Order article via Infotrieve]
- Zanchetti A., Ruilope LM Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20:2099-110.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003.
- Alderman MH, Cohen H., Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999;33:1130-4.[Abstract/Free Full Text]
- Shimamoto M., Shiiki M., Ise T. et al. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 1994;8:755-9.[Web of Science][Medline]
[Order article via Infotrieve]
- Savage PJ, Pressel SL, Curb JD et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension:The Systolic Hypertension in the Elderly Program. Arch Intern Med 1998;158:741-51.[Abstract/Free Full Text]
- Lindholm LH, Ibsen H., Borch-Johnsen K. et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. JHypertens 2002;20:1879-86.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sharma AM, Janke J., Gorzelniak K., Engeli S., Luft FC Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002;40:609-11.[Abstract/Free Full Text]
- Thorand B., Lowel H., Schneider A. et al. C-reactive protein as a predictor for incident diabetes mellitus among middleaged men: Results from the MONICA augsburg cohort study, 1984-1998. Arch Intern Med 2003;163:93-9.[Abstract/Free Full Text]
- Pradhan AD, Manson JE, Rifai N., Buring JE, Ridker PM Creactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.[Abstract/Free Full Text]
- The Diabetes Prevention Research Group. Reduction in the incidence of type 2 diabetes with lifestyle modification or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
- Teutsch S. The cost of preventing diabetes: What do we know and what do we need to know? Diabetes Care 2003; 26:238-9.[Free Full Text]
- Gress TW, Nieto FJ, Shahar E., Wofford MR, Brancati FL Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-12.[Abstract/Free Full Text]
- Chiasson JL, Josse RG, Gomis R., Hanefeld M., Karasik A., Laakso M.Acarbose for prevention of type 2 diabetes mellitas: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Raji A., Seely EW, Bekins SA, Williams GH, Simonson DC Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.Diabetes Care 2003;26:172-8.[Abstract/Free Full Text]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 3,
169-170 (2003)
DOI: 10.3317/jraas.2003.026
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. J. Zillich, J. Garg, S. Basu, G. L. Bakris, and B. L. Carter
Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review
Hypertension,
August 1, 2006;
48(2):
219 - 224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Sharma
Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?
Hypertension,
July 1, 2004;
44(1):
12 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
